09:41 AM EST - Bausch + Lomb Corporation : Announced the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation. Bausch + Lomb Corporation
shares T.BLCO are trading unchanged at $23.87.
